Karyopharm Therapeutics (NASDAQ:KPTI - Get Free Report) will issue its quarterly earnings data before the market opens on Tuesday, November 5th. Analysts expect the company to announce earnings of ($0.27) per share for the quarter. Karyopharm Therapeutics has set its FY 2024 guidance at EPS.Individual interested in registering for the company's earnings conference call can do so using this link.
Karyopharm Therapeutics (NASDAQ:KPTI - Get Free Report) last released its earnings results on Tuesday, August 6th. The company reported ($0.20) EPS for the quarter, topping analysts' consensus estimates of ($0.29) by $0.09. The business had revenue of $42.79 million for the quarter, compared to the consensus estimate of $36.07 million. On average, analysts expect Karyopharm Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
Karyopharm Therapeutics Price Performance
Shares of NASDAQ KPTI traded down $0.09 during mid-day trading on Friday, reaching $0.90. 1,697,228 shares of the company's stock were exchanged, compared to its average volume of 1,276,340. The firm has a market capitalization of $112.61 million, a price-to-earnings ratio of -0.83 and a beta of 0.20. Karyopharm Therapeutics has a 52 week low of $0.62 and a 52 week high of $1.95. The firm has a 50-day moving average price of $0.80 and a two-hundred day moving average price of $0.92.
Wall Street Analysts Forecast Growth
Several equities research analysts recently weighed in on KPTI shares. StockNews.com raised Karyopharm Therapeutics from a "hold" rating to a "buy" rating in a report on Thursday, August 8th. HC Wainwright reissued a "buy" rating and issued a $7.00 price objective on shares of Karyopharm Therapeutics in a report on Friday. Royal Bank of Canada reissued an "outperform" rating and issued a $3.00 price objective on shares of Karyopharm Therapeutics in a report on Wednesday, August 7th. Finally, Robert W. Baird decreased their price objective on Karyopharm Therapeutics from $8.00 to $5.00 and set an "outperform" rating for the company in a report on Wednesday, August 7th. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company presently has an average rating of "Buy" and an average price target of $5.00.
Get Our Latest Stock Report on KPTI
About Karyopharm Therapeutics
(
Get Free Report)
Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).
See Also
Before you consider Karyopharm Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Karyopharm Therapeutics wasn't on the list.
While Karyopharm Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
